Get the Stockscreener App
6.09
1.33%
0.08
After Hours:
6.18
0.09
+1.48%
Cybin Inc stock is traded at $6.09, with a volume of 539.58K.
It is up +1.33% in the last 24 hours and down -20.18% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$6.01
Open:
$6.05
24h Volume:
539.58K
Relative Volume:
1.19
Market Cap:
$143.66M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-29.32
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-9.51%
1M Performance:
-20.18%
6M Performance:
-17.03%
1Y Performance:
-20.23%
1-Day Range:
$5.98
$6.17
1-Week Range:
$5.98
$6.668
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.09 | 148.15M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Best data tools to analyze Cybin Inc. stockJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
Cybin Executives to Present at TD Cowen Neuropsychiatry Summit on Novel Mental Health Treatments - citybuzz -
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Investigation Opened on Behalf of Cybin Inc. (CYBN) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
CYBN Completes Phase 2 Study Enrollment for Anxiety Disorder Tre - GuruFocus
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - Yahoo Finance
Cybin Inc. Securities Lawsuit Investigation - Claim Depot
Cybin (OTCMKTS:CLXPF) Trading 12.5% HigherWhat's Next? - MarketBeat
Aug Rallies: What dividend growth rate does Cybin Inc. offerWeekly Stock Summary & Low Drawdown Momentum Ideas - Lancaster City Council
What’s the analyst consensus on Cybin Inc.Quarterly Risk Review & Comprehensive Market Scan Insights - Lancaster City Council
Cybin Inc. Hits Oversold Level on RSI IndicatorWeekly Trading Summary & Community Verified Trade Alerts - beatles.ru
Cybin completes enrollment in phase 2 anxiety disorder study - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc.CYBN - PR Newswire
Cybin completes enrollment in phase 2 anxiety disorder study By Investing.com - Investing.com Canada
Cybin (CYBN) Completes Enrollment for Phase 2 Anxiety Disorder S - GuruFocus
Cybin completes phase 2 enrollment evaluating CYB004 for the treatment of generalized anxiety disorder - MarketScreener
300M Anxiety Patients Could Benefit: Cybin's Novel DMT Drug Reaches Key Trial Milestone - Stock Titan
Investors Hope for Bounce in Cybin Inc. After Selloff2025 Valuation Update & AI Forecast Swing Trade Picks - beatles.ru
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Can Cybin Inc. lead its sector in growthQuarterly Profit Report & Smart Swing Trading Alerts - classian.co.kr
Can Cybin Inc. reach all-time highs this yearخودرو بانک - خودرو بانک
Cybin (OTCMKTS:CYBN) Shares Down 16.6%Here's Why - MarketBeat
Can swing trading help recover from Cybin Inc. lossesJuly 2025 Outlook & Weekly Return Optimization Alerts - Newser
What dividend growth rate does Cybin Inc. offerWeekly Trade Recap & High Conviction Buy Zone Picks - خودرو بانک
Is Cybin Inc. in a long term uptrendWeekly Market Outlook & High Accuracy Swing Trade Signals - خودرو بانک
Has Cybin Inc. Stock Ever Crashed Historical Volatility ReviewJuly 2025 PostEarnings & Detailed Earnings Play Strategies - Newser
Why Cybin Inc. is moving todayMarket Trend Review & Low Drawdown Trading Techniques - Newser
Will Cybin Inc. price bounce be sustainableTake Profit & Growth Oriented Trade Recommendations - Newser
Is Cybin Inc. forming a breakout patternTrade Risk Summary & High Accuracy Buy Signal Tips - خودرو بانک
Chipmakers Recap: Can Cybin Inc. lead its sector in growthDay Trade & Verified Swing Trading Watchlist - خودرو بانک
Real time social sentiment graph for Cybin Inc.Market Growth Summary & Stock Portfolio Risk Control - Newser
Should you wait for a breakout in Cybin Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Public market insider buying at Cybin (CYBN) - The Globe and Mail
What to expect from Cybin Inc. in the next 30 daysMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Can Cybin Inc. be the next market leader2025 Short Interest & Accurate Entry and Exit Point Alerts - خودرو بانک
What does recent volatility data suggest for Cybin Inc.Weekly Profit Summary & Weekly High Potential Stock Alerts - Newser
Cybin Inc. to Present at H.C. Wainwright Global Investment Conference - citybuzz -
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - MarketScreener
Leading Neuropsychiatry Company Cybin to Showcase Progress at Major Investment Conference - Stock Titan
Is Cybin Inc. a good ESG investmentJuly 2025 Market Mood & Community Trade Idea Sharing Platform - خودرو بانک
Is Cybin Inc. affected by consumer sentimentWeekly Risk Report & AI Powered Buy/Sell Recommendations - خودرو بانک
Cybin Inc. shares rise 3.49% premarket after announcing participation in Cantor Global Healthcare Conference. - AInvest
Exit strategy if you’re trapped in Cybin Inc.Weekly Trade Analysis & Verified Trade Idea Suggestions - Newser
Cybin Inc. shares rise 1.00% after-hours as Chief Medical Officer to participate in Cantor Global Healthcare Conference. - AInvest
Analyzing drawdowns of Cybin Inc. with statistical toolsGlobal Markets & Smart Money Movement Tracker - Newser
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Neuropsychiatry Pipeline - citybuzz -
Is Cybin Inc. a potential multi baggerWeekly Earnings Recap & AI Enhanced Market Trend Forecasts - خودرو بانک
Cybin to Participate in Cantor Global Healthcare Conference 2025 with Fireside Chat by CMO Amir Inamdar - AInvest
Cybin to Participate in the Cantor Global Healthcare Conference 2025 - FinancialContent
Regression analysis insights on Cybin Inc. performanceJuly 2025 Summary & High Conviction Buy Zone Alerts - Newser
Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - MSN
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Cap:
|
Volume (24h):